-

01:40:14 PM

APDN Stock News

APDN - Applied Dna Sciences Inc

02/11/21 7:00 AM

Nasdaq : APDN

low float

Applied DNA and Cytocheck Detect First Instance of SARS-CoV-2 B.1.1.7 Variant in Kansas

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Cytocheck Laboratory, LLC (Cytocheck), an anatomic and clinical pathology laboratory, today reported that Cytocheck identified the first instance of a SARS-CoV-2

RHEA-AI

neutral

02/05/21 7:00 AM

Nasdaq : APDN

earningslow float

Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021

Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same

RHEA-AI

neutral

02/02/21 10:00 AM

Nasdaq : APDN

covid-19low float

Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has qualified a freeze-dried (lyophilized) form of its LinearDNA™ COVID-19 vaccine candidate for its upcoming feline clinical trial. Lyophilization

RHEA-AI

neutral

01/26/21 9:41 AM

NYSE, Nasdaq : TTT, APDN

TruTrace Technologies™ and Applied DNA Unveil Complete Cannabis Product Validation and Authentication Solution

TruTrace Technologies, Inc. (CSE: TTT) (“TruTrace” or the “Company”), developer of a fully-integrated blockchain platform for the legal cannabis, food and pharmaceutical industries, today announced the signing of a definitive agreement with Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”),

RHEA-AI

positive

01/26/21 8:00 AM

Nasdaq, NYSE : APDN, TTT

low float

Applied DNA and TruTrace Technologies™ Unveil Complete Cannabis Product Validation and Authentication Solution

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the signing of a definitive agreement with TruTrace Technologies, Inc. (CSE: TTT) (“TruTrace”), developer of a fully-integrated blockchain platform for the

RHEA-AI

positive

01/20/21 7:00 AM

Nasdaq : APDN

low float

Applied DNA Promotes Judith Murrah to Chief Operating Officer

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the promotion of Chief Information Officer Judith Murrah to the role of Chief Operating Officer effective immediately. The promotion formalizes Ms.

RHEA-AI

very positive

01/19/21 7:00 AM

Nasdaq : APDN

covid-19low float

Applied DNA Linea™ COVID-19 Assay Kit Demonstrates Effectiveness with Detection of Multiple SARS-CoV-2 Variants During Recent Surveillance Testing

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the “Assay Kit”) identified COVID-19 positive samples that are variants distinct from the wild-type virus that has

RHEA-AI

neutral

01/15/21 7:00 AM

Nasdaq, NYSE : APDN, APPDW

covid-19low float

Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing

Applied DNA Sciences, Inc. (NASDAQ:APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle™ pooled surveillance testing service has seen a 158% increase in the daily average number of tests performed to date in January 2021

RHEA-AI

very positive

01/13/21 11:44 AM

Nasdaq : APDN

offeringlow float

Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with a group of institutional investors of 1,810,000 shares of common stock at a price

RHEA-AI

neutral

01/11/21 7:00 AM

Nasdaq : APDN

offeringlow float

Applied DNA Announces Pricing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,810,000 shares of

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next

APDN Data:

IndustryCyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Websitehttps://adnas.com
CeoJames Hayward
Security nameApplied Dna Sciences Inc
Issue typecs
SectorManufacturing
Sic code2865
Employees60
Tags
- Manufacturing
- Technology Services
- Cyclic Crude
- Intermediate
- and Gum and Wood Chemical Manufacturing
- Health Technology
- Pharmaceuticals: Major
- Miscellaneous Commercial Services
- Commercial Services
- Information Technology Services
Address50 Health Sciences Dr
StateNew York
CityStony Brook
Zip11790-3349
CountryUS
Phone16312408800

APDN Description:

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.